Every Form 4 that FibroBiologics, Inc. (FBLG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBLG filings page.
FibroBiologics, Inc. (FBLG) reported that Chief Scientific Officer Hamid Khoja acquired 298,508 shares of common stock on September 15, 2026 at $1.675 per share in a private placement, together with warrants to purchase up to 298,508 additional shares at an exercise price of $1.55 per share, exercisable until September 15, 2031. Following these awards, he holds 301,571 shares of common stock directly, along with 298,508 warrants.
FibroBiologics, Inc. director Robert E. Hoffman reported receiving a grant of stock options. He was awarded stock options covering 30,803 shares of common stock at an exercise price of $0.7503 per share, expiring on June 22, 2036. These options will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting. Following this compensation-related grant, Hoffman holds 30,803 stock options directly.
FibroBiologics, Inc. director Richard C. Cilento Jr. reported a grant of stock options. He received options to acquire 30,803 shares of common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting and expire on June 22, 2036.
FibroBiologics, Inc. director Matthew Link received a grant of stock options covering 30,803 shares of common stock. The options have an exercise price of $0.7503 per share and expire on June 22, 2036. Following this grant, he holds options for 30,803 shares directly. The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting.
FibroBiologics, Inc. director Niklas Victoria Ninon Olivia received a grant of 30,803 stock options to buy common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of grant or the next annual meeting and expire on June 22, 2036. Following this award, Olivia directly holds 30,803 options.
FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.
According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.
FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.
FibroBiologics, Inc. Chief Scientific Officer Hamid Khoja reported an open-market purchase of 30,000 shares of common stock at $0.3800 per share. Following this transaction, he directly owns 61,250 common shares.
FibroBiologics, Inc. chief executive officer Pete O'Heeron reported open-market purchases of 51,500 shares of common stock across three days. He bought 17,428 shares on March 2, 18,200 on March 3, and 15,872 on March 4, 2026, bringing his direct holdings to 5,958,147 shares.
FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026. The weighted average purchase price was $0.4139 per share, with individual trade prices ranging from $0.3968 to $0.4200. Following this transaction, Davis directly owns 70,000 common shares.
FibroBiologics, Inc. General Counsel Ruben A. Garcia bought 40,000 shares of common stock in an open-market purchase on February 27, 2026 at a weighted average price of $0.3264 per share. After this transaction, he directly owns 180,000 shares. The filing notes individual trade prices ranged from $0.3221 to $0.3268.
FibroBiologics, Inc. insider activity shows that general counsel Ruben A. Garcia purchased 140,000 shares of common stock on December 11, 2025. The Form 4 reports this as a purchase coded “P” at a weighted average price of $0.34 per share, with individual trade prices ranging from $0.3333 to $0.3504. After these transactions, Garcia beneficially owns 140,000 shares of FibroBiologics common stock, held directly.